Testosterone Blood Test: Total, Free, and Optimal Ranges Explained

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Hormone testing and interpretation should be conducted in consultation with a qualified healthcare practitioner. Reference ranges cited are indicative and may vary by laboratory and individual context.

Testosterone is one of the most commonly tested hormones in men over 40, yet the results are routinely misinterpreted — sometimes in ways that matter clinically. A man can present with textbook symptoms of low androgens: reduced libido, poor recovery, low mood, cognitive sluggishness, loss of muscle mass, and increased central adiposity. His total testosterone comes back within the laboratory reference range and he is told everything is fine. The result is technically accurate and clinically misleading at the same time.

The reason is that total testosterone measures what is in circulation — not what is available to tissues. Bioavailability is governed primarily by sex hormone-binding globulin (SHBG), and interpreting a testosterone result without understanding SHBG is like reading a bank balance without knowing how much of it is locked in a fixed-term account.

What Total Testosterone Actually Measures

Total testosterone is measured from a venous blood sample using either radioimmunoassay (RIA) or the more accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. LC-MS/MS is the gold standard — it is more specific and avoids the cross-reactivity issues that can inflate RIA results, particularly in women or individuals with elevated adrenal hormone levels. Most major Australian pathology laboratories now use LC-MS/MS for testosterone measurement.

The total testosterone result captures all testosterone in circulation, which exists in three distinct fractions:

• SHBG-bound testosterone: approximately 60–65% of the total. Testosterone bound to SHBG is held with high affinity and is essentially biologically inactive at the tissue level. SHBG-bound testosterone cannot enter cells and cannot bind androgen receptors.
• Albumin-bound testosterone: approximately 33–35% of the total. This fraction is bound loosely and is considered bioavailable — albumin releases testosterone readily in capillary beds where it can diffuse into tissue.
• Free testosterone: approximately 2–3% of the total. Entirely unbound, freely diffusible into cells, and immediately biologically active.

The combined albumin-bound and free fractions — sometimes called "bioavailable testosterone" — represent the portion that tissues can actually use. When SHBG is elevated, a larger proportion of total testosterone is locked in the biologically inert SHBG-bound fraction, reducing bioavailability even as the total figure remains normal or high.

Australian Reference Ranges vs Functional Targets

Reference ranges published by Australian pathology services and referenced at ptex.au list the adult male range for total testosterone as approximately 8.0–29.0 nmol/L. The width of this range — nearly fourfold — is a direct reflection of the fact that it is derived from a population spanning all adult ages. A 22-year-old elite athlete and a 78-year-old sedentary man both fall within this reference population.

Testosterone declines physiologically with age at approximately 1–2% per year after age 30 (Travison et al. longitudinal cohort data), so a result of 9.5 nmol/L is technically within range whether it belongs to a 30-year-old or a 75-year-old, despite representing very different functional states. This is why functional medicine and some endocrinologists use age-stratified or symptom-integrated targets rather than relying solely on population reference intervals.

Functional targets frequently cited in the androgen literature:

• Younger men (under 40): 15–25 nmol/L is often cited as a target range associated with optimal androgen activity in symptomatic evaluation, though this is a clinical convention rather than a defined diagnostic threshold.
• Men over 50: A result of 12–18 nmol/L may be more age-appropriate; interpretation must weight both the number and the clinical picture.
• Women (all ages): 0.3–2.4 nmol/L per standard Australian laboratory reference intervals. Free testosterone interpretation is equally critical in women given the tighter total range and the outsized effect of even modest SHBG shifts.

The total testosterone number, read in isolation against a broad reference range, cannot reliably distinguish between a man with adequate androgen exposure and one with functional hypogonadism. Free testosterone and SHBG are required to complete the picture.

Free Testosterone: The Biologically Active Fraction

Free testosterone — the 2–3% of total testosterone that is unbound — is what drives androgen receptor activity in muscle, bone, brain, and reproductive tissue. It is the fraction that matters most for the symptoms patients report.

The problem is measurement. Direct measurement of free testosterone by equilibrium dialysis is the gold standard: serum is dialysed against a buffer at physiological conditions, and the concentration in the buffer reflects the true free fraction. It is accurate, reproducible, and expensive. It is also not routinely available through standard Australian pathology services, and even when ordered, pre-analytical handling requirements make results variable between laboratories.

The practical alternative — and the one in widespread clinical use — is calculated free testosterone using the Vermeulen formula. This calculation takes total testosterone, SHBG, and albumin (typically assumed at 4.3 g/dL if not measured directly) as inputs and derives an estimated free testosterone. The Vermeulen method has been validated against equilibrium dialysis and is considered clinically acceptable for routine interpretation. Online calculators implementing this formula are freely available and are routinely used by endocrinologists and sports medicine physicians when a laboratory does not provide a direct free T measurement.

Indicative reference ranges for free testosterone in men:

• Standard laboratory range: approximately 170–670 pmol/L (varies by method and laboratory)
• Functional targets in symptomatic assessment often flag concern below 200–220 pmol/L in younger men

When a man's total testosterone sits at 14 nmol/L but his SHBG is 65 nmol/L, the calculated free testosterone may fall below 200 pmol/L — consistent with symptomatic androgen deficiency despite a total result that appears only modestly reduced.

SHBG: The Key Variable

Sex hormone-binding globulin is a glycoprotein produced by the liver that acts as a carrier for testosterone, oestradiol, and dihydrotestosterone (DHT) in circulation. It does not simply reflect androgen levels — it actively determines how much testosterone is bioavailable. SHBG is the dominant regulator of free testosterone concentration, and its level is influenced by a wide range of physiological and pathological states.

Conditions that elevate SHBG (reducing bioavailable testosterone):

• Ageing (SHBG rises roughly 1–2% per year from middle age)
• Elevated oestrogen (from exogenous oestrogen, obesity with aromatisation, or oestrogen-producing pathology)
• Hyperthyroidism (thyroid hormones strongly upregulate hepatic SHBG production)
• Liver disease
• Caloric restriction and very low-carbohydrate diets
• Some anticonvulsant medications

Conditions that suppress SHBG (increasing bioavailable testosterone — not always beneficial):

• Obesity and insulin resistance (hyperinsulinaemia suppresses hepatic SHBG production)
• Hypothyroidism
• Elevated androgen levels (endogenous or exogenous)
• Nephrotic syndrome (urinary SHBG loss)

Suppressed SHBG with low total testosterone — a pattern commonly seen in insulin-resistant men — can produce a deceptively normal or mildly reduced total testosterone alongside preserved free testosterone. The metabolic context is unfavourable, but the androgen picture looks less alarming on paper than the underlying biology warrants. Low SHBG is itself an independent predictor of incident type 2 diabetes and metabolic syndrome, which is worth noting when a result comes back in the low-normal range.

Pattern Interpretation

Reading testosterone results as patterns rather than isolated numbers substantially increases diagnostic yield. The following combinations are the most clinically instructive:

Normal total T + low free T + high SHBG: Testosterone is being produced but a disproportionate fraction is locked to SHBG. Bioavailable testosterone is genuinely reduced. Clinical hypogonadism can occur despite a normal total testosterone result. This is one of the most commonly missed patterns in men in their 40s and 50s — particularly those who are lean, have elevated oestrogen, or have subclinical hyperthyroidism driving SHBG upwards.

Low total T + low SHBG: Calculate free testosterone before drawing conclusions. In the setting of insulin resistance or obesity, SHBG suppression can partially preserve free testosterone even as total falls. This may be secondary hypogonadism, obesity-related hypogonadism, or a combination — but free T may be disproportionately maintained relative to total T.

Low total T + high LH and FSH: Primary hypogonadism. The pituitary is driving testicular stimulation harder (elevated gonadotropins) but testosterone production is failing. Causes include testicular damage from orchitis, cryptorchidism, radiation, Klinefelter syndrome, or age-related Leydig cell decline.

Low total T + low LH and FSH: Secondary hypogonadism. The signal from the hypothalamic-pituitary axis is suppressed, leading to reduced testicular stimulation. Common drivers include chronic psychological stress with HPA axis suppression (see cortisol awakening response and HPA function), severe caloric restriction, sleep deprivation, hyperprolactinaemia, and pituitary pathology. This pattern warrants investigation of sleep, stress burden, and pituitary imaging when severe.

Oestradiol: The Essential Addition

Testosterone does not exist in isolation from oestrogen in men. Aromatase — encoded by the CYP19A1 gene and expressed at highest concentration in adipose tissue — converts testosterone to oestradiol (E2). This conversion is physiologically normal and necessary: oestradiol in men contributes to bone mineral density, cardiovascular health, libido, and mood regulation. Problems arise when the testosterone-to-oestradiol ratio becomes unfavourable.

Oestradiol should be checked alongside testosterone in any male hormone panel. The LC-MS/MS assay (sometimes called "sensitive" or "ultrasensitive" E2) is significantly more accurate than standard immunoassay at the lower concentrations found in men — immunoassay E2 in men is unreliable and should be specifically requested as the sensitive method.

Oestradiol reference ranges in men:

• Standard laboratory range: approximately 40–160 pmol/L
• Functional practitioners often target 70–150 pmol/L, with some citing a narrower 90–130 pmol/L as optimal

Both ends of this range are problematic. Very low oestradiol (below 50–60 pmol/L) in men is associated with poor libido, reduced bone density, joint aches, and dysphoria — symptoms that can paradoxically accompany testosterone treatment in men who use aromatase inhibitors too aggressively. Very high oestradiol (above 180–200 pmol/L) correlates with water retention, gynaecomastia, emotional lability, and further SHBG elevation — which compounds free testosterone suppression.

LH and FSH: Single Most Useful Addition

If a single additional test beyond total testosterone and SHBG were to be added to a male hormone panel, LH and FSH provide the most interpretive leverage at the lowest cost. These gonadotropins are produced by the anterior pituitary and drive testicular testosterone and sperm production respectively.

Their primary utility is distinguishing primary from secondary hypogonadism:

• Low testosterone + elevated LH and FSH = primary hypogonadism (testicular failure; pituitary is compensating)
• Low testosterone + low or normal LH and FSH = secondary hypogonadism (hypothalamic or pituitary signal deficiency)

This distinction matters for management. Primary hypogonadism typically requires exogenous testosterone replacement; secondary hypogonadism may respond to lifestyle correction, treatment of underlying causes (sleep, stress, weight), or — in selected fertility-relevant cases — gonadotropin stimulation. Grouping both presentations under a single "low testosterone" label and applying the same approach is a clinical oversimplification that LH and FSH data readily prevents.

What Lowers Testosterone

Several modifiable factors have meaningful evidence for reducing testosterone in men:

Sleep deprivation: Among the most potent modifiable suppressants. Leproult and Van Cauter (2011) demonstrated in a controlled study that one week of five-hour nights reduced daytime testosterone levels by approximately 10–15% in healthy young men. The mechanism involves disruption of the nocturnal LH pulse pattern that drives overnight testicular testosterone synthesis. This connects directly to the DHEA-S and adrenal reserve picture — sleep restriction simultaneously elevates cortisol and reduces both testosterone and DHEA-S.

Excess body fat: Adipose tissue is the primary site of peripheral aromatase activity. Greater adiposity means greater testosterone-to-oestradiol conversion, higher circulating oestradiol, further SHBG elevation, and downstream suppression of the hypothalamic-pituitary-gonadal (HPG) axis through oestrogen's negative feedback on the hypothalamus.

Chronic psychological stress and elevated cortisol: Cortisol directly inhibits testicular steroidogenesis at the Leydig cell level and suppresses hypothalamic GnRH pulsatility. Men under sustained occupational or psychological stress routinely show suppressed testosterone alongside elevated evening cortisol.

Alcohol: Directly toxic to Leydig cells at higher intake levels; also impairs hepatic oestrogen clearance and can increase SHBG. Even moderate intake has modest suppressive effects in some studies.

Severe caloric restriction: Signals energetic scarcity to the hypothalamus, which deprioritises reproductive function. Testosterone falls significantly in response to prolonged caloric deficit — relevant for competitive athletes in weight-class sports and anyone undergoing aggressive fat loss phases.

Endocrine-disrupting compounds: Phthalates and bisphenol A (BPA) carry epidemiological associations with reduced testosterone and altered sperm parameters. The mechanistic evidence in humans remains associative rather than conclusively causal, but cumulative environmental EDC exposure is a plausible contributor in chronically symptomatic men.

Soy isoflavones: At pharmacological doses — well above typical dietary consumption — weak oestrogenic activity has been demonstrated in some studies. At normal dietary levels, the evidence for meaningful testosterone suppression in men is weak and inconsistent.

Testing in Australia

A comprehensive male hormone panel ordered for androgen assessment should include:

1. Total testosterone (LC-MS/MS where available; morning draw essential)
2. SHBG
3. Albumin (needed for Vermeulen free T calculation if not directly measured)
4. Oestradiol (sensitive or ultrasensitive LC-MS/MS assay in men specifically)
5. LH and FSH (to classify hypogonadism type if total T is reduced)
6. Free testosterone (calculated via Vermeulen if not directly measured by dialysis)

Timing is critical. Testosterone secretion follows a strong circadian pattern, peaking between 8 and 10am and declining through the afternoon. Afternoon testosterone draws can be 20–30% lower than morning levels in the same individual on the same day. All testosterone testing should be conducted as a morning fasting draw, ideally between 7 and 10am. A single result in the borderline range should be confirmed on a second morning draw before clinical decisions are made.

Reference ranges for Australian pathology are documented at ptex.au, though as noted above, the broad reference interval for total testosterone makes pattern interpretation and free testosterone calculation essential companions to the raw number.

Medicare typically covers testosterone testing when symptoms of hypogonadism are clinically documented by the requesting practitioner. SHBG and LH and FSH are generally also covered in this context. Sensitive oestradiol may require private billing depending on the requesting clinician and the laboratory.

For those exploring the broader context of hormone optimisation research, the mechanistic literature on testosterone, SHBG, and androgen receptor sensitivity continues to evolve — particularly in relation to ageing, metabolic health, and recovery physiology.

Summary

Total testosterone is the starting point, not the conclusion. The biologically meaningful question is how much testosterone is actually reaching androgen receptors — and that is determined by the free and albumin-bound fractions, which in turn depend on SHBG.

A complete interpretation requires total testosterone, SHBG, calculated (or measured) free testosterone, oestradiol, and LH and FSH. The pattern of these values — not any single number — identifies whether the clinical picture reflects primary or secondary hypogonadism, SHBG-driven bioavailability suppression, metabolic-driven shifts, or a genuinely adequate androgen environment.

Timing the draw correctly (morning, fasted), using the right assay (LC-MS/MS for both testosterone and oestradiol in men), and interpreting results against physiologically meaningful targets rather than age-conflated reference ranges are the practical steps that separate a useful testosterone assessment from a misleading one.